Back to search
Anthracycline Related Cardiotoxicity in Breast Cancer
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Anthracycline Related Cardiotoxicity in Breast Cancer trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Anthracycline Related Cardiotoxicity in Breast Cancer trials you may qualify forCardiotoxicity is heart damage that arises from certain drugs, such as those used for cancer treatment and develops in approximately 10% of patients with breast…
Cancer treatments have improved substantially over the past decades, but some effective therapies such as anthracyclines and HER2-targeted agents are associated…
Breast cancer is the most commonly cancer in women in the overall global population. According to the World Cancer Research Fund International, there were more…
Cardiomyopathy is a major complication of doxorubicin (DOX) chemotherapy, and 10-21% of breast cancer patients receiving DOX experience compromised cardiac func…
The goal of this clinical trial is to compare a dietary intervention with a regular diet in patients with early breast cancer undergoing anthracycline based che…
Breast cancer is the most common form of cancer in women. Modern breast cancer treatments have led to increased survival, but at the same time, increased risk f…
The main goal of this study is to test a virtual reality (VR) program, Survivors' Virtual Reality Survivorship Experience (SurviVRSE), designed to help Breast C…
This study, called "ROSUBREAST", is a multicenter, double-blind, randomized clinical trial evaluating whether rosuvastatin (20 mg daily) can protect the heart i…